Single gene shot could tame rare enzyme disorder

NCT ID NCT06818838

First seen Jan 23, 2026 · Last updated Apr 23, 2026 · Updated 10 times

Summary

This early-phase study tests a single-dose gene therapy called LY-M001 in 12 adults with type 1 Gaucher disease, a genetic condition that causes organ enlargement and bone problems. The therapy uses a harmless virus to deliver a working copy of the GBA1 gene to the liver, so the body can produce the missing enzyme. The main goals are to check safety and see if the treatment can improve enzyme levels and reduce liver and spleen size.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangzhou First People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hematology Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, Tianjin Municipality, 300011, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanxi Bethune Hospital

    RECRUITING

    Taiyuan, Shanxi, 030000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.